Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
Inebilizumab delivers lasting results in MG treatment. Dr. Suraj Muley highlights that inebilizumab demonstrates durable responses at 52 weeks in both AChR+ and MuSK+ myasthenia gravis patients with no new safety concerns. He argues it stands apart from downstream therapies by targeting autoantibody production at its source — the B cell.
Inebilizumab is making a case for itself as a meaningful upstream option in the treatment of myasthenia gravis (MG). Neurologist Dr. Suraj Muley synthesizes clinical data showing durable responses at 52 weeks in patients with both AChR+ and MuSK+ subtypes of MG — with no new safety signals emerging over that period.
Dr. Muley draws a clear distinction between inebilizumab and other available therapies. Unlike complement inhibitors and FcRn blockers — which act downstream — inebilizumab targets B cells, the source of autoantibody production. This upstream mechanism, he argues, may translate into more sustained and durable treatment responses compared to therapies that don't address the root cause.
Key Takeaways
Why it matters: For clinicians managing MG, the choice of therapy increasingly hinges on mechanism of action. Inebilizumab's upstream B cell targeting offers a differentiated approach that may provide more lasting disease control — a critical consideration for patients with refractory or hard-to-treat MG.
